

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

## In Re Application of:

Evan C. Unger, et al.

Serial No.: 09/218,660


Group Art Unit: 1619

Filing Date: December 22, 1998

Examiner: S. Sharareh

For: NOVEL TARGETED COMPOSITIONS FOR DIAGNOSTIC AND  
THERAPEUTIC USEDATE OF DEPOSIT: JULY 17, 2001

I HEREBY CERTIFY THAT THIS PAPER IS BEING  
DEPOSITED WITH THE UNITED STATES POSTAL  
SERVICE AS FIRST CLASS MAIL, POSTAGE PREPAID  
ON THE DATE INDICATED ABOVE AND IS ADDRESSED  
TO THE ASSISTANT COMMISSIONER FOR PATENTS,  
WASHINGTON, DC 20231.

  
TYPED NAME: S. Maurice Valla  
REGISTRATION NO.: 43,966

Assistant Commissioner for Patents  
Washington DC 20231

Dear Sir:

## CERTIFICATION UNDER 37 C.F.R. §1.97(e)


In accordance with 37 C.F.R. §1.97(e), certification is hereby made that:

- Each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the Information Disclosure Statement.
- No item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after

making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in §1.56(c) more than three months prior to the filing of the information disclosure statement.


Date:

*July 17, 2001*

  
\_\_\_\_\_  
S. Maurice Valla  
Registration No. 43,966

Woodcock Washburn Kurtz  
Mackiewicz & Norris LLP  
One Liberty Place - 46th Floor  
Philadelphia PA 19103  
Telephone: (215) 568-3100  
Facsimile: (215) 568-3439

© 2000 WWKMN



DOCKET NO.: DUP-0307

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

GAUCH 619 REC'D  
TECH OFFICE 10/25/01  
PATENT CENTER 1600/2900  
10/25/01  
RECEIVED

In Re Application of:

  
Evan C. Unger, et al.

Serial No.: 09/218,660

Group Art Unit: 1619


Filing Date: December 22, 1998

Examiner: S. Sharareh

For: NOVEL TARGETED COMPOSITIONS FOR DIAGNOSTIC AND  
THERAPEUTIC USE

DATE OF DEPOSIT: July 17, 2001

I HEREBY CERTIFY THAT THIS PAPER IS BEING  
DEPOSITED WITH THE UNITED STATES POSTAL  
SERVICE-AS-FIRST-CLASS-MAIL, POSTAGE-PREPAID  
ON THE DATE INDICATED ABOVE AND IS ADDRESSED  
TO THE ASSISTANT COMMISSIONER FOR PATENTS,  
WASHINGTON, DC 20231.

  
TYPED NAME: S. Maurice Valla  
REGISTRATION NO.: 43,966

Assistant Commissioner for Patents  
Washington DC 20231

Dear Sir:

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**

Pursuant to 37 C.F.R. §1.56 and in accordance with 37 C.F.R. §§1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 C.F.R. §1.56(b).

In accordance with §1.97(b), since this Information Disclosure Statement is being filed either within three months of the filing date of the above-identified application, within three months of the date of entry into the national stage of the above identified application as set forth in §1.491, before the mailing date of a first Office Action on the merits of the above-identified application, or before the mailing date of a first office action after the filing of request for continued examination under §1.114, no additional fee is required.

- In accordance with §1.129(a), this Information Disclosure Statement is being filed in connection with  the first or  second After Final Submission, therefore:
  - Certification in Accordance with §1.97(e) is attached; or
  - The fee of \$180.00 as set forth in §1.17(p) is attached.
- In accordance with §1.97(c), this Information Disclosure Statement is being filed after the period set forth in §1.97(b) above but before the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311, or before an action that otherwise closes prosecution in the application, therefore:
  - Certification in Accordance with §1.97(e) is attached; or
  - The fee of \$180.00 as set forth in §1.17(p) is attached.
- In accordance with §1.97(d), this Information Disclosure Statement is being filed after the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311 but before, or simultaneously with, the payment of the Issue Fee, therefore included are: Certification in Accordance with §1.97(e); and the submission fee of \$180.00 as set forth in §1.17(p).
- Copies of each of the references listed on the attached Form PTO-1449 are enclosed herewith.
- Copies of references listed on the attached Form PTO-1449 are enclosed herewith EXCEPT THAT:
  - In view of the voluminous nature of references [list as appropriate], and the likelihood that these references are available to the Examiner, copies are not enclosed herewith.

- In accordance with §1.98(d), copies of the following references listed on the attached Form PTO-1449 are not enclosed herewith because they were previously cited by or submitted to the U.S. Patent and Trademark Office in patent application(s) for which a claim for priority under 35 U.S.C. §120 have been made in the instant application:
- Copies of references [list as appropriate] listed on the attached Form PTO-1449 were previously cited by or submitted to the Patent and Trademark Office in prior application Serial No. , filed .
- If any of the foregoing publications are not available to the Examiner, Applicant will endeavor to supply copies at the Examiner's request.

Please charge any deficiency or credit any overpayment to Deposit Account No. 23-3050.

This form is submitted in duplicate.

Enclosed is a copy of the European Search Report dated April 23, 2001, which indicates the references considered to be relevant.

An English language abstract has been provided for those references which are not in the English language.

Date: *July 17, 2001*

  
S. Maurice Valla  
S. Maurice Valla  
Registration No. 43,966

WOODCOCK WASHBURN KURTZ  
MACKIEWICZ & NORRIS LLP  
One Liberty Place - 46th Floor  
Philadelphia, PA 19103  
Telephone: (215) 568-3100  
Facsimile: (215) 568-3439